Chronic Kidney Disease of uncertain etiology
Conditions
Interventions
1.The study subjects will be recruited from the patients diagnosed with CKDu undergoing hemodialysis, who attend the nephrology hemodialysis units in Teaching Hospital, Anuradhapura.
2. The randomiza
Sponsors
National Science Foundation
Eligibility
Inclusion criteria
Inclusion criteria: All consenting CKDu patients, both male and female, undergoing hemodialysis who attend the nephrology hemodialysis units 18 years old or above. Chronic Kidney Disease of Uncertain etiology diagnosed clinically and biochemically by medical officers in the nephrology units of study hospitals
Exclusion criteria
Exclusion criteria: Patients with a history of renal transplantation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug adherence. A Brief Medication questionnaire will be used to measure the drug adherence of the patients. Ref. Svarstad, B.L., Chewning, B.A., Sleath, B.L., Claesson, C. (1999) The brief medication questionnaire: A tool for screening patient adherence and barriers to adherence. Patient Education and Counselling, (37):113-124 [At the date of recruitment (baseline) and twelve months after the date of recruitment (post intervention)] Appropriateness of prescribing. Medication appropriateness index (MAI) will be used as a tool. [At the date of recruitment (baseline) and twelve months after the date of recruitment (post intervention)] Medication related problems. Drug related problem classification system created by the Pharmaceutical Care Network of Europe, the latest version of Australian Medicines Handbook (AMH) and the British National Formulary (BNF) will be used as a reference. to identify, classify and prevent the medication related problems [At the date of recruitment (baseline) and twelve months after the date of recruitment (post intervention)] | — |
Secondary
| Measure | Time frame |
|---|---|
| The disease management outcome will be assessed based on laboratory parameters. 1. Serum calcium 2. Serum phosphate 3. Blood urea nitrogen-BUN 4. URR 5. Hemoglobin 6. Lipid profile. Relative changes in these parameters will be assessed compared to each baseline values. [Blood investigations will be done at the date of recruitment (baseline) and twelve months after the date of recruitment (post intervention) ] Novel renal injury biomarkers: 1. NGAL 2. KIM-1 3. Clusterin 4. Cystatin C 5. IL-18 6. Beta2- microglobulin. The measurement of these biomarkers will be done using standard multiplex assays. [ Panel of novel renal injury biomarkers will be measured in the urine samples collected at each visit (at baseline, 2, 6, 10 and 12 months post-recruitment in the intervention group and at baseline and at 12 months in the control group)] | — |
Countries
Sri Lanka
Contacts
Public ContactDr. Shaluka Jayamanne
Consultant Physician, Senior Lecturer in Medicine Department of Medicine
Outcome results
None listed